News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics Announces Certain Preliminary 2021 Unaudited Financial Results
Preliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of  December 31, 2021 TUCSON, Ariz. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose
View HTML
Toggle Summary HTG Completes HTP Product Next-Phase Development Milestone
Expands Potential Market and Study Opportunities for HTG Transcriptome Panel TUCSON, Ariz. , Dec. 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology,
View HTML
Toggle Summary HTG Expands Therapeutics Scientific Advisory Board With Addition of Dr. Jerald Radich
Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular Genetics TUCSON, Ariz. , Dec. 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its
View HTML
Toggle Summary HTG Announces Major Sales Milestone for HTG Transcriptome Panel
Recognizes More Than $1 Million of HTP Revenue Through November 2021 TUCSON, Ariz. , Dec. 09, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced
View HTML
Toggle Summary HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling
View HTML
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that, on November 9, 2021 the Compensation Committee of the
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Third Quarter 2021 Results
Call scheduled for today, November 10, at 4:30 pm ET TUCSON, Ariz. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2021 Financial Results and Host Conference Call on Wednesday, November 10
TUCSON, Ariz. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021
View HTML
Toggle Summary HTG Expands Therapeutics Team
Veteran Drug Developer Stephen Barat, Ph.D. Joins to Head Company’s Therapeutics Division TUCSON, Ariz. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
TUCSON, Ariz. , Sept. 21, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will present in a fireside chat in Cantor Fitzgerald’s Virtual Global Healthcare
View HTML